ArticleNeurology(R) neuroimmunology & neuroinflammation2026
HLA and T-Cell Receptor Investigations in Idiopathic and Paraneoplastic Opsoclonus-Myoclonus in Children.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesOpsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare pediatric autoimmune neurologic disorder, with 40%-50% of cases occurring as a paraneoplastic syndrome in the setting of neuroblastoma or other neuroblastic tumors. The strong clinical similarities between idiopathic and paraneoplastic OMAS have led to the hypothesis that neuroblastoma may initially be present in idiopathic cases but spontaneously regress before OMAS onset. Both B- and T-cell mechanisms appear to contribute to OMAS autoimmunity, although their precise roles remain unknown. The aim of this study was to investigate similarities and differences between idiopathic and paraneoplastic OMAS by analyzing HLA profiles and T-cell receptor (TCR) repertoires in a Spanish pediatric cohort.
methodsChildren with OMAS were enrolled in a nationwide prospective study (2013-2024). Neural autoantibody testing was performed in all patients. HLA genotyping was performed using next-generation sequencing (GenDx/Illumina) and compared with a reference Spanish population (n = 4,335). The Benjamini-Hochberg false discovery rate method was used to control for multiple comparisons across HLA antigens. TCR repertoires were analyzed in peripheral blood samples of 12 patients using the Adaptive Biotechnologies immunoSEQ assay. The bioinformatics tool Grouping of Lymphocyte Interactions by Paratope Hotspots (GLIPH2) was used to identify shared motifs within CDR3β-TCR sequences.
resultsAmong 25 children with OMAS (median age 22 months [interquartile range (IQR): 15-38]), 12 (48%) had neuroblastoma and 3 (12%) had neuronal antibodies (one with anti-Hu, one with anti-myelin oligodendrocyte glycoprotein, one against unknown neuronal surface antigens). Some HLA class II antigens (DRB1*08, DRB1*10, and DQB1*04) were consistently overrepresented in patients with OMAS compared with Spanish controls (all DISCUSSION: Despite similar clinical presentations, idiopathic and paraneoplastic OMASs appear to have distinct immunopathogenic mechanisms. In paraneoplastic OMAS, enrichment of specific HLA antigens and convergent TCR profiles supports antigen-driven T cell-mediated autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.